Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia

The goal of this clinical trial is to learn if pacritinib works better than hydroxyurea to treat advanced proliferative chronic myelomonocytic leukemia in adults. The main questions it aims to answer are: * Does pacritinib improve disease control compared to hydroxyurea? * What medical problems do participants have when taking pacritinib or hydroxyurea? Researchers will compare pacritinib to hydroxyurea to see if pacritinib is more effective and better tolerated in people with advanced proliferative chronic myelomonocytic leukemia. Participants will be randomly assigned to receive either pac

Trial Details

NCT ID
NCT07033598
Phase
PHASE2
Sponsor
Theradex
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Pacritinib
  • Hydroxyurea
Locations (sample)
  • Tampa, Florida, United States|27.94752,-82.45843
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • Houston, Texas, United States|29.76328,-95.36327
  • London, Greater London, United Kingdom|51.50853,-0.12574

Key Eligibility Criteria

  • Diagnosis of CMML-1 (5th WHO classification), with \<10% bone marrow blasts on morphology and \<5% peripheral blood blasts.
  • Proliferative disease, defined as white blood cell count ≥13 × 10⁹/L.
  • Advanced disease, defined as at least one of the following features during screening: spleen palpable ≥5cm below the lower costal margin in the mid…
  • ECOG performance status ≤2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →